Maria Jesus Rubio - Department of Medical Oncology, Hospital Universitario Reina Sofia

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 45 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Palbociclib Plus Letrozole in Estrogen Receptor-Positive Advanced/recurrent Endometrial Cancer: Double-blind Placebo-Controlled Randomized Phase II ENGOT-EN3/PALEO Trial

Mansoor R. Mirza,Line Bjorge,Frederik Marme, Rene DePont Christense,Marta Gil-Martin,Annika Auranen,Beyhan Ataseven,Maria Jesus Rubio,Vanda Salutari,Adam A. Luczak,Ingo B. Runnebaum,Andres Redondo,Kristina Lindemann,Fabian Trillsc, M. Pilar Barretina Ginesta,Henrik Roed,Jean-Emmanuel Kurtz, Karen S. Petersson,Gitte-Bettina Nyvang,Jalid Sehouli

GYNECOLOGIC ONCOLOGY (2025): 128-136

Cited0Views0WOSBibtex

Cemiplimab in Recurrent Cervical Cancer: Final Analysis of Overall Survival in the Phase III EMPOWER-Cervical 1/Gog-3016/Engot-cx9 Trial

Ana Oaknin,Bradley J. Monk,Andreia Cristina de Melo,Hee Seung Kim,Yong Man Kim,Alla S. Lisyanskaya,Vanessa Samouelian,Domenica Lorusso,Fernanda Damian,Chih-Long Chang, Evgeniy Gotovkin,Shunji Takahashi, Daniella Ramone,Beata Mackowiak-Matejczyk,Laura Polastro,Eva Maria Guerra Alia,Nicoletta Colombo, Yulia Makarova,Jeffrey C. Goh,Kosei Hasegawa,Paulo Mora,Joanna Pikiel, Ratnesh Srivastav,Danny Rischin,Maria Jesus Rubio, Javier Perez,Suk Young Yoo,Bo Gao, Shaheda Jamil,Frank Seebach,Israel Lowy,Melissa Mathias,Matthew G. Fury,Krishnansu S. Tewari

EUROPEAN JOURNAL OF CANCER (2025)

Cited0Views0WOSBibtex

Figure S2 from Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or Without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/MINOVA Study)

Beatriz Tavira,Teresa Iscar,Luis Manso,Ana Santaballa,Marta Gil-Martin, García,Margarita Romeo,Maria Iglesias,Ana de Juan Ferré,María Pilar Barretina-Ginesta,Aranzazu Manzano,Lydia Gaba,María Jesús Rubio,Carlos E. de Andrea,Antonio González-Martín

openalex（2024）

Cited0Views0Bibtex

Supplementary Methods 1 from Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or Without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/MINOVA Study)

openalex（2024）

Cited0Views0Bibtex

Table S1 from Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or Without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/MINOVA Study)

openalex（2024）

Cited0Views0Bibtex

DOMENICA Study (Gineco-En105b/engot-en13): Randomized Phase III Trial in MMR Deficient (mmrd) Endometrial Cancer (EC) Patients Comparing Chemotherapy (CT) Alone Versus Dostarlimab in First Line Advanced/metastatic Setting (APGOT-EN1)

Proceedings of the 39th Annual Meeting of the Korean Society of Gynecologic Oncology (2024)

Cited0Views0Bibtex

Figure S3 from Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or Without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/MINOVA Study)

openalex（2024）

Cited0Views0Bibtex

Atezolizumab Combined with Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer with a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial

JOURNAL OF CLINICAL ONCOLOGYno. 36 (2024)

Cited1Views0WOSBibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn